Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma / 国际口腔科学杂志·英文版
International Journal of Oral Science
;
(4): 16-16, 2020.
Article
in English
| WPRIM
| ID: wpr-828962
ABSTRACT
With the understanding of the complex interaction between the tumour microenvironment and immunotherapy, there is increasing interest in the role of immune regulators in the treatment of head and neck squamous cell carcinoma (HNSCC). Activation of T cells and immune checkpoint molecules is important for the immune response to cancers. Immune checkpoint molecules include cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), T-cell immunoglobulin mucin protein 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), T cell immunoglobin and immunoreceptor tyrosine-based inhibitory motif (TIGIT), glucocorticoid-induced tumour necrosis factor receptor (GITR) and V-domain Ig suppressor of T cell activation (VISTA). Many clinical trials using checkpoint inhibitors, as both monotherapies and combination therapies, have been initiated targeting these immune checkpoint molecules. This review summarizes the functional mechanism and use of various immune checkpoint molecules in HNSCC, including monotherapies and combination therapies, and provides better treatment options for patients with HNSCC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Therapeutics
/
Therapeutic Uses
/
Tumor Microenvironment
/
Squamous Cell Carcinoma of Head and Neck
/
Head and Neck Neoplasms
/
Immunologic Factors
/
Immunotherapy
/
Methods
Limits:
Humans
Language:
English
Journal:
International Journal of Oral Science
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS